These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 9327093)
21. Evidence of a disturbance of the hypothalamic-pituitary-adrenal axis in polycystic ovary syndrome: effect of naloxone. Lanzone A; Guido M; Ciampelli M; Fulghesu AM; Pavone V; Proto C; Caruso A; Mancuso S Clin Endocrinol (Oxf); 1996 Jul; 45(1):73-7. PubMed ID: 8796141 [TBL] [Abstract][Full Text] [Related]
22. Effects of budesonide by means of the Turbuhaler on the hypothalmic-pituitary-adrenal axis in asthmatic subjects: a dose-response study. Aaronson D; Kaiser H; Dockhorn R; Findlay S; Korenblat P; Thorsson L; Källén A J Allergy Clin Immunol; 1998 Mar; 101(3):312-9. PubMed ID: 9525445 [TBL] [Abstract][Full Text] [Related]
23. Plasma B-endorphin levels in patients with self-injurious behavior and stereotypy. Sandman CA; Barron JL; Chicz-DeMet A; DeMet EM Am J Ment Retard; 1990 Jul; 95(1):84-92. PubMed ID: 2167106 [TBL] [Abstract][Full Text] [Related]
24. Acute HPA axis responses, heart rate, and mood changes to psychosocial stress (TSST) in humans at different times of day. Kudielka BM; Schommer NC; Hellhammer DH; Kirschbaum C Psychoneuroendocrinology; 2004 Sep; 29(8):983-92. PubMed ID: 15219648 [TBL] [Abstract][Full Text] [Related]
25. Effects of self-administered cocaine on plasma adrenocorticotropic hormone and cortisol in male rhesus monkeys. Broadbear JH; Winger G; Cicero TJ; Woods JH J Pharmacol Exp Ther; 1999 Jun; 289(3):1641-7. PubMed ID: 10336563 [TBL] [Abstract][Full Text] [Related]
26. Hypothalamic-pituitary-adrenocortical (HPA) axis response and biotransformation of oral naltrexone: preliminary examination of relationship to family history of alcoholism. King AC; Schluger J; Gunduz M; Borg L; Perret G; Ho A; Kreek MJ Neuropsychopharmacology; 2002 Jun; 26(6):778-88. PubMed ID: 12007748 [TBL] [Abstract][Full Text] [Related]
27. Disregulation of proopiomelanocortin and contagious maladaptive behavior. Sandman CA; Touchette P; Marion S; Lenjavi M; Chicz-Demet A Regul Pept; 2002 Oct; 108(2-3):179-85. PubMed ID: 12220743 [TBL] [Abstract][Full Text] [Related]
28. Alcohol urge and plasma beta-endorphin change after alcohol challenge with naltrexone pretreatment in social drinkers. Na C; Lee YS Prog Neuropsychopharmacol Biol Psychiatry; 2002 May; 26(4):663-70. PubMed ID: 12188097 [TBL] [Abstract][Full Text] [Related]
29. Nalmefene causes greater hypothalamic-pituitary-adrenal axis activation than naloxone in normal volunteers: implications for the treatment of alcoholism. Schluger JH; Ho A; Borg L; Porter M; Maniar S; Gunduz M; Perret G; King A; Kreek MJ Alcohol Clin Exp Res; 1998 Oct; 22(7):1430-6. PubMed ID: 9802524 [TBL] [Abstract][Full Text] [Related]
30. Naltrexone as a treatment of self-injurious behavior--a case report. Griengl H; Sendera A; Dantendorfer K Acta Psychiatr Scand; 2001 Mar; 103(3):234-6. PubMed ID: 11240582 [TBL] [Abstract][Full Text] [Related]
31. Blunted opiate modulation of hypothalamic-pituitary-adrenocortical activity in men and women who smoke. al'Absi M; Wittmers LE; Hatsukami D; Westra R Psychosom Med; 2008 Oct; 70(8):928-35. PubMed ID: 18799426 [TBL] [Abstract][Full Text] [Related]
32. Proopiomelanocortin (POMC) sequencing and developmental delay: Preliminary evidence for a SNP in the 3' UTR region of the POMC gene-Possible relevance for biological risk and self-injurious behavior. Damerow JA; Tervo RC; Ehrhardt M; Panoskaltsis-Mortari A; Symons FJ Dev Psychopathol; 2019 May; 31(2):433-438. PubMed ID: 30009717 [TBL] [Abstract][Full Text] [Related]
33. Neuroendocrine responses to intravenous infusion of physostigmine in patients with Alzheimer disease. Asthana S; Raffaele KC; Greig NH; Schapiro MB; Blackman MR; Soncrant TT Alzheimer Dis Assoc Disord; 1999; 13(2):102-8. PubMed ID: 10372954 [TBL] [Abstract][Full Text] [Related]
34. Using analog baselines to assess the effects of naltrexone on self-injurious behavior. Garcia D; Smith RG Res Dev Disabil; 1999; 20(1):1-21. PubMed ID: 9987807 [TBL] [Abstract][Full Text] [Related]
35. Sex differences in pain and hypothalamic-pituitary-adrenocortical responses to opioid blockade. al'Absi M; Wittmers LE; Ellestad D; Nordehn G; Kim SW; Kirschbaum C; Grant JE Psychosom Med; 2004; 66(2):198-206. PubMed ID: 15039504 [TBL] [Abstract][Full Text] [Related]
36. Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults. Double-blind placebo-controlled studies. Willemsen-Swinkels SH; Buitelaar JK; Nijhof GJ; van England H Arch Gen Psychiatry; 1995 Sep; 52(9):766-73. PubMed ID: 7654128 [TBL] [Abstract][Full Text] [Related]
37. Naltrexone and self-injurious behavior: a retrospective population study. Casner JA; Weinheimer B; Gualtieri CT J Clin Psychopharmacol; 1996 Oct; 16(5):389-94. PubMed ID: 8889912 [TBL] [Abstract][Full Text] [Related]
38. Temporal patterns of self-injurious behavior correlate with stress hormone levels in the developmentally disabled. Kemp AS; Fillmore PT; Lenjavi MR; Lyon M; Chicz-Demet A; Touchette PE; Sandman CA Psychiatry Res; 2008 Jan; 157(1-3):181-9. PubMed ID: 17913241 [TBL] [Abstract][Full Text] [Related]
39. The use of opiate antagonists for recurrent self-injurious behavior. Buzan RD; Thomas M; Dubovsky SL; Treadway J J Neuropsychiatry Clin Neurosci; 1995; 7(4):437-44. PubMed ID: 8555746 [TBL] [Abstract][Full Text] [Related]